Travere Therapeutics

TVTX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$30.44

-3.12% today

52W: $12.91 – $42.13

52W Low: $12.91 Position: 60% 52W High: $42.13

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

7.14x

Forward Price/Earnings

P/S Ratio

5.72x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.8B

Market Capitalization

Revenue Growth

73.4%

YoY Revenue Growth

Profit Margin

-5.21%

Net profit margin

ROE

-57.8%

Return on Equity

Beta

0.87

Market sensitivity

Short Interest

14.61%

% of float sold short

Avg. Volume

1,925,952

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

14 analysts

Avg. Price Target

$42.50

+39.62% upside

Target Range

$31.00 – $49.00

About the Company

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in th

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 497 Exchange: NGM